Europe Acute Respiratory Distress Syndrome (ARDS) Market, By Cause (Coronavirus Disease 2019 (COVID-19), Sepsis, Inhalation of Harmful Substances, Severe Pneumonia, and Others), Type (Diagnosis, and Treatment), Route of Administration (Oral, Parenteral, and Others), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others), Country (Germany, U.K., Italy, France, Spain, Switzerland, Russia, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Netherlands, and the Rest of Europe), Industry Trends and Forecast to 2029.
Europe Acute Respiratory Distress Syndrome (ARDS)Market Analysis and Size
Acute respiratory distress syndrome (ARDS) is a life-threatening lung injury that allows fluid to leak into the lungs. Most people who get ARDS are already hospitalized for trauma or illness like COVID-19. The syndrome usually occurs when fluids build up in the lungs in tiny, elastic air sacs called alveoli. This fluid build-up causes less oxygen to reach the bloodstream. This deprives the organs of getting enough oxygen for their normal function. People with other illness develops ARDS within a few hours to days after the precipitating injury or infection. The risk of death increases with age, and depending on the severity of the illness, patients surviving the syndrome becomes hard. Severe illness or injury causes damage to the membrane sacs of the lungs, leading to ARDS. The most common underlying causes for the said diseases include sepsis, inhalation of harmful substances, severe pneumonia, head, chest, or another major injury, coronavirus disease 2019 (COVID-19), and others.
Increasing prevalence and incidence of acute lung injury, a wide range of risk factors for ARDS, and acceleration in a patient pool of COVID-19 with ARDS act as drivers for the acute respiratory distress syndrome (ARDS) market. The other factors which are anticipated to propel the growth of the Europe acute respiratory distress syndrome (ARDS) market include the rising rate of air pollution and lifestyle-related diseases and Increasing accident rates and trauma-causing ARDS.
However, the factors such as the complications associated with treatments and the high cost of devices and treatments hamper the growth of the Europe acute respiratory distress syndrome (ARDS) market. On the other hand, the growing geriatric population, rising healthcare expenditure, and strategic Initiatives by market players act as an opportunity for the growth of the Europe acute respiratory distress syndrome (ARDS) market. The stringent Regulations for approval and multiple challenges faced by ICU nurses is the key market challenge faced in the Europe acute respiratory distress syndrome (ARDS) market.
Data Bridge Market Research analyses that the Europe Acute Respiratory Distress Syndrome (ARDS) market is expected to reach a value of USD 5,291.89 million by 2029, at a CAGR of 9.5% during the forecast period. "Coronavirus Disease 2019 (COVID-19)" accounts for the most prominent technology segment due to its wide infectious and contagious nature, progressively developing respiratory illnesses such as pneumonia and acute respiratory distress syndrome. The acute respiratory distress syndrome (ARDS) market report also comprehensively covers pricing analysis, patent analysis, and technological advancements.
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Segments Covered
|
By Cause (Coronavirus Disease 2019 (COVID-19), Sepsis, Inhalation of Harmful Substances, Severe Pneumonia, and Others), Type (Diagnosis, and Treatment), Route of Administration (Oral, Parenteral, and Others), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others).
|
|
Countries Covered
|
Germany, U.K., Italy, France, Spain, Switzerland, Russia, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Netherlands, and the Rest of Europe.
|
|
Market Players Covered
|
Drägerwerk AG & Co. KGaA, Fisher & Paykel Healthcare Limited., LivaNova PLC, Gilead Sciences, Inc., Fresenius SE & Co. KGaA, Armstrong Medical, Smiths Medical, ResMed, Medtronic, F. Hoffmann-La Roche Ltd, Hamilton Medical, nice Neotech Medical Systems Pvt. Ltd., Pfizer Inc., Terumo Medical Corporation, Getinge AB., and EUROSETS, among others.
|
Market Definition
Acute respiratory distress syndrome (ARDS) is a life-threatening lung injury that allows fluid to leak into the lungs. Most people who get ARDS are already hospitalized for trauma or illness like COVID-19. The syndrome usually occurs when fluids build up in the lungs' tiny, elastic air sacs called alveoli. This fluid build-up causes less oxygen to reach the bloodstream. This deprives the organs of getting enough oxygen for their normal function. People with other illnesses develop ARDS within a few hours to days after the precipitating injury or infection. The risk of death increases with age, and depending on the severity of the illness, patients surviving the syndrome becomes hard.
Severe illness or injury which causes damage to the membrane sacs of the lungs leads to ARDS. The most common underlying causes for the said diseases include sepsis, inhalation of harmful substances, severe pneumonia, head, chest, another major injury, coronavirus disease 2019 (COVID-19), and others.
Acute Respiratory Distress Syndrome (ARDS) Market Dynamics
This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail as below:
Drivers
- Increasing prevalence and incidence of acute lung injury
The increasing alcohol consumption, irrespective of age, leads to syndrome-like ARDS. Other risk factors like dyspnoea, hypertension, diabetes, and more lead to ARDS development. Thereby, this wide range of risk factors associated with acute respiratory distress syndrome increases the possibility of developing the clinical condition, simultaneously raising the cases of the disease. These affirmative risk factors are anticipated to boost the growth of the market.
- Wide range of risk factors for ARDS
The increasing alcohol consumption, irrespective of age, leads to syndrome-like ARDS. Other risk factors like dyspnoea, hypertension, diabetes, and more lead to ARDS development. Thereby, this wide range of risk factors associated with acute respiratory distress syndrome increases the possibility of developing the clinical condition, simultaneously raising the cases of the disease. These affirmative risk factors are anticipated to boost the growth of the market.
- Acceleration in the patient pool of COVID-19 with ARDS
The rising number of COVID-19 cases also increases the chance of acute respiratory distress syndrome among people, which is expected to act as a driver for the growth of the acute respiratory distress syndrome market.
- Rising rate of air pollution and lifestyle-related diseases
The World Health Organization, air pollution is one of the greatest environmental risks to health by increasing the burden of diseases like heart diseases and lung and respiratory infections at both acute and chronic levels. Hence, the rising air pollution rate in developed and developing countries increases the chances of people getting syndromes like acute respiratory distress syndrome. Thus, the factor is expected to drive the growth of the market.
- Increasing accident rates and trauma causing ARDS
The inhalation of smoke releases materials like fibrin, neutrophils, mucus, and epithelial cell debris that occlude the airway lumen, causing changes in ventilation. This condition leads to hypoxemia which is a primary significant reason for ARDS. They also reported that increased mortality rates in burn patients were due to ARDS. Thereby, the rising accidents and trauma injuries in the lungs are expected to drive the growth of the market
Restraint
- Complications associated with treatments
There are treatments for ARDS helping people survive, but the complications associated with treatments and post-treatment are still a burden for patients. Most potential and lasting effects include breathing problems, depression, problems with memory and thinking, tiredness and muscle weakness, and more.
These complications associated with and post-treatment of acute respiratory distress syndrome are expected to hamper the market growth during our forecast period.
- High cost of device and treatments
The high cost of ventilation treatment per day is not affordable if the therapy has to proceed for many days. Hence patients prefer taking ventilators for home care. However, the price of ventilators is yet quite expensive. Therefore, the high cost of treatment and ventilators is very challenging for people to afford any reliable remedy for the long term until the patient completely recovers. This is anticipated to hamper the growth of the market.
- Lack of skilled workforce
There were shortages of nurses even before the pandemic began in the U.S. as the region has a high number of population with respiratory disorders. Therefore, the lack of appropriately skilled and trained nurses in the ICU will be a more remarkable restraint expected to hamper the growth of the acute respiratory distress syndrome (ARDS) market.
Post COVID-19 Impact on Acute Respiratory Distress Syndrome (ARDS) Market
The pandemic of COVID-19, the rising prevalence of acute respiratory distress syndrome and lung failure, which is commonly seen in COVID-19 patients, has increased the demand for ventilators, respiratory equipment, peak flow meters, and the treatment products like antiviral and steroidal drugs in hospitals and this is accelerating the market growth. Therefore, during this pandemic, the demand for ventilators, humidifiers, respiratory inhalers, and certain drugs for respiratory healing problems is very high. According to the situation report of 6th January 2022 by WHO stated, 288.86 million cumulative cases of coronavirus have been reported globally, and 5.43 million patients are dead due to the coronavirus. America is leading in cumulative cases with a record of 104.69 million and 2.4 million death rates, followed by Europe with 103 million cumulative cases and 1.67 million cumulative deaths. The outbreak of COVID-19 is having a huge impact on the healthcare and supply chain of various medical products, including respiratory products and ventilators.
COVID-19 is a serious concern in the new era, where ARDS (Acute Respiratory Distress Syndrome) and lung failure are most commonly seen in COVID-19 patients. As reported by healthcare professionals, pneumonia caused by the SARS-CoV-2 virus usually presents with fever, dyspnea, and acute respiratory symptoms, which can lead to ARDS, a life-threatening form of respiratory failure. Therefore this sudden surge of COVID-19 patients and associated ARDS illness, the demand for the market is higher in this forecasted period.
It is anticipated that the COVID-19 pandemic outbreak will have a positive impact on the growth of the market due to the enormous requirement and application of such products for respiratory disorders, COVID-19 infection, ARDS, and more. The company’s manufacturing and supply process resumed with steady ease of supply restrictions made by the government recently worldwide.
Moreover, International governments of Europe healthcare organizations have supported the supply of these products due to their high priority in this crucial health crisis period. Many government bodies and significant market players are closely associated with patients and pharma industries for secure packaging of products and drugs considering the contagious nature of the virus and improvement of future economics.
Recent Development
- In January 2020, ResMed Debuts AirTouch N20 Foam CPAP Mask, Its Softest Nasal Mask Ever - ResMed’s first nasal memory foam cushion enhanced patients’ comfort and convenience, and it didn’t need cleaning when replaced on an appropriate schedule. AirTouch N20 was the latest offering in ResMed’s line of easy-to-use, convenient, and more comfortable masks. This has helped the company to expand its product portfolio.
- In February 2021, Pfizer Inc. CentreOne announced the new campaign of API & Intermediates. This campaign focused on a comprehensive range of complex API compounds and intermediates for drug product developers and manufacturers. This campaign launch helped the company to enhance in the U.S. market.
Europe Acute Respiratory Distress Syndrome (ARDS) Market Scope
The acute respiratory distress syndrome (ARDS) market is segmented on the basis of cause, type, route of administration, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
By Cause
- Coronavirus Disease 2019 (Covid-19)
- Sepsis
- Inhalation of Harmful Substances
- Severe Pneumonia
- Others
On the basis of cause, the Europe acute respiratory distress syndrome (ARDS) market is segmented into coronavirus disease 2019 (COVID-19), sepsis, inhalation of harmful substances, severe pneumonia, and others.
By Type
- Diagnosis
- Treatment
On the basis of type, the Europe acute respiratory distress syndrome (ARDS) market is segmented into diagnosis, and treatment.
By Route of Administration
- Oral
- Parental
- Others
On the basis of route of administration, the Europe acute respiratory distress syndrome (ARDS) market is segmented into oral, parenteral, and other.
By End User
- Hospitals
- Specialty Clinics
- Home Healthcare
- Others
On the basis of end users, the Europe acute respiratory distress syndrome (ARDS) market is segmented into hospitals, specialty clinics, home healthcare, and others.
By Distribution Channel
- Direct Tender
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
On the basis of distribution channel, the Europe acute respiratory distress syndrome (ARDS) market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy, and others.
Acute Respiratory Distress Syndrome (ARDS) Market Regional Analysis/Insights
The acute respiratory distress syndrome (ARDS) market is analyzed, and market size insights and trends are provided by cause, type, route of administration, end user, and distribution channel, as referenced above.
The countries covered in the acute respiratory distress syndrome (ARDS) market report are Germany, the U.K., Italy, France, Spain, Switzerland, Russia, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Netherlands, and the Rest of Europe.
Germany dominates the Europe acute respiratory distress syndrome (ARDS) market. Germany dominates the market due to increasing research activities and rising biotechnology and pharmaceuticals in the region. This will boost the demand for Acute Respiratory Distress Syndrome (ARDS) products in the Europe region.
The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends, porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing a forecast analysis of the country data.
Competitive Landscape and Acute Respiratory Distress Syndrome (ARDS) Market Share Analysis
The acute respiratory distress syndrome (ARDS) market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Europe presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the acute respiratory distress syndrome (ARDS) market.
SKU-